10x Genomics (TXG) Misses Q2 EPS by 22c

10x Genomics (NASDAQ: TXG) reported Q2 EPS of ($0.57), $0.22 worse than the analyst estimate of ($0.35). Revenue for the quarter came in at $114.6 million versus the consensus estimate of $117.64 million.

GUIDANCE:

10x Genomics sees FY2022 revenue of $500-520 million, versus the consensus of $571 million.

For earnings history and earnings-related data on 10x Genomics (TXG) click here.

You May Also Be Interested In

• Westinghouse said to seek over $50 billion valuation in planned IPO
• UBS cuts KOSPI target by nearly 10% to reflect higher rates
• DraftKings Inc. (DKNG) PT Lowered to $48 at UBS on Updated Estimates Post Q2